Oxford UK, July 16th, 2026. Theolytics, a clinical‑stage biotechnology company developing next‑generation oncolytic immunotherapies, announces that it has relocated to new, state‑of‑the‑art facilities at ARC Oxford, a growing science and innovation campus close to Oxford’s world‑class research institutes, teaching hospitals and university. The company joins a thriving community of more than 30 science and technology companies at ARC Oxford, further strengthening the campus’ position as a hub for cutting‑edge innovation.
Founded in 2017 as a spinout from the University of Oxford, Theolytics is working to develop best‑in‑class oncolytic immunotherapies for complex and difficult‑to‑treat solid tumours. Leveraging its proprietary Adenovo™ platform, the company has pioneered a new approach to develop efficacious, targeted adenoviral candidates suitable for direct and intravenous delivery targeting stroma‑rich tumours, a feature of major cancers including ovarian, colorectal, pancreatic ductal adenocarcinoma and triple‑negative breast cancer.